BIOY targets biotech companies with meaningful dividend yields — a rare combination since most biotechs reinvest everything into R&D. This ETF uses a covered call overlay strategy to manufacture additional income from what's typically a growth-oriented, non-dividend-paying sector.
How It Works
The fund holds dividend-paying biotech stocks (think established pharma-biotech hybrids like Amgen or Gilead, not clinical-stage startups) and writes covered calls on the portfolio to generate extra yield. This 'YieldBOOST' approach trades away upside potential for current income — you're essentially selling your lottery tickets each month for cash. The strategy works best in sideways or mildly bullish markets where option premiums stay rich but stocks don't rocket past strike prices.
Key Features
- Generates 5-7% yield from a sector that typically yields under 1% through systematic option writing
- Focuses on profitable biotechs with actual products and cashflow, not speculative drug developers
- Monthly distributions combining dividends and option premiums provide steady income stream
Risks
- Covered calls cap upside at 2-4% monthly, so you'll miss biotech's famous 50%+ acquisition pops
- Biotech volatility means the underlying stocks can drop 20-30% on clinical trial failures while you collect 0.5% monthly premiums
- Zero AUM suggests this product may face liquidation risk — check daily volumes before buying
Who Should Own This
Best for income investors who want biotech exposure but can't stomach the sector's volatility without getting paid to wait. Works as a 2-5% satellite position for retirees seeking yield beyond traditional dividend aristocrats. Absolutely wrong for anyone expecting to capture biotech's growth potential — this strategy explicitly trades growth for income.